x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Dr RR Baliga"s "Got Knowledge Doc" Podkast

Dr RR Baliga, MD, MBA

"Got Knowledge Doc" Podkast with Dr. RR Baliga The "Got Knowledge Doc" Podkast, hosted by Dr. Ragavendra R. Baliga, is a knowledge-driven platform designed for physicians and healthcare providers seeking to stay at the forefront of medical science and innovation. With a distinguished career in cardiovascular medicine and academic leadership, Dr. Baliga engages with leading experts to explore cutting-edge research, emerging technologies, and transformative insights in medicine and beyond. Each

science natural sciences

All Episodes

03:24

Dr RR Baliga's Philosophical Discourses: Dogen...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/16

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—“just sitting” 🧘‍♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

en

05:11

NSTEMI: 📉 Less Ischemia, Less Reintervention

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/05

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI

en

06:04

Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/05

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure

en

03:20

The AMALFI AF Screening Trial-📈 Atrial Fibrillation...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/04

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG

en

05:14

🛑 AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/04

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care. 🔗 #AFib

en

05:16

🦠💔Bugged After the Heartbreak? Does H. pylori...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/03

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75) 🧠 Key Takeaway: Routine screening isn’t broadly warranted—but targeted testing in

en

03:33

🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌡️...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/02

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let’s rethink how we label, risk-stratify, and treat. 📚 #VTE #Apixaban

en

04:04

Dr RR Baliga's Philosophical Discourses: Zhu Xi...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/02

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨ #Leadership #Philosophy #History #Confucianism

en

05:23

Gait Speed. Grip Strength. Greater Life. 🦵🤝🌟 A...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/01

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5%. No serious adverse events. And yes — better gait speed, handgrip strength, and quality of life too. This is how we shift from survival ➡️ functional

en

04:03

💊 Block. Beat. Benefit. The Hidden Strength of...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/01

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)? 📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clinical heart failure. 🌍 Consistent across trials and countries. Most benefit seen in patients <75 years. 📚 This could shift guidelines for a large

en

04:59

🧠 REBOOTing Beta-Blockers – No Gains ⚖️ After Modern...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/31

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%). 💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Signals of potential harm in women and STEMI subgroups raise questions, not answers. 📉 Should

en

04:49

Beta Blockers in MI: Old Drug, New Lens, Possible Win...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/31

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there’s no heart failure? 🤔 In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉 📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p=0.03 💡 Especially lowered risk of recurrent MI (HR 0.73) 🧠 Even in the era of PCI, DAPT & statins,

en

06:07

🧬 ICDs. K⁺ Boost. Fewer Jolts

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/30

💥 New NEJM Trial Alert! A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀 📉 HR 0.76 for the composite endpoint 🔢 NNT = 12.3 over 3.3 years 🍌 Safe, scalable, and globally relevant 👉 Time to rethink “normal” K⁺ levels in cardiology! #Cardiology #Electrophysiology #NEJM #ICD #Potassium #POTCAST

en

06:01

🫀 Foxglove, Frailty, and HFrEF — Digitoxin in...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/30

🚨 New RCT Alert from the NEJM! Can an old 💊 make a comeback in modern 💓 failure care? 📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i. 🩺 HR = 0.82; p = 0.03 📉 👩‍⚕️ Safe in CKD, consistent benefit in women. ⚠️ Serious AEs slightly higher (4.7% vs 2.8%) 📥 NNT = 22. 💡Is it

en

10:04

From Sclerosis 🧱 to Stenosis 🚪 to Surgery 🔧

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/29

🚨 Calcific Aortic Valve Stenosis (CAVS): Beyond Wear and Tear 🫀🪨 Once thought to be “degenerative,” CAVS is now recognized as an active disease driven by oxidative stress ⚡, inflammation 🔥, and lipoprotein(a) 🧬. Despite its growing global burden, no drug therapy slows its progression. 🩺 Current management: Surgical (SAVR) or Transcatheter (TAVR) valve replacement. 💊 Emerging hope: PCSK9 inhibitors, Lp(a) lowering agents, SGLT2 inhibitors, soluble guanylate cyclase activators, and

en

04:44

💊📉 Mix, Match, and Lower: Predicting BP Drops with...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/29

🚨 New in The Lancet (2025) 🚨 A mega meta-analysis of 484 RCTs (104K+ participants) offers a game-changing approach to hypertension management! 💊📉 Instead of guessing how much BP will drop, now you can predict it—by drug, dose, and combo! 🎯 Like statins for LDL, this study introduces low-, moderate-, and high-intensity BP regimens based on expected mmHg reductions. 💡 Use the free calculator 🔢 at www.bpmodel.org and rethink the “measure-treat-measure” loop. 🩺 Data-driven. Predictable

en

04:43

Partial Hearts. Whole Hope. Lasting Change. 🧩❤️🔬 A...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/28

🧒❤️ Partial Heart Transplant: A Growing Solution for Growing Hearts! 🌱🔬 🚨 Pediatric patients with congenital heart valve disease often face multiple surgeries due to non-living valve grafts that don’t grow. This landmark study from @DukeHealth shows how living valves via partial heart transplant can change the game. 📊 In 19 patients (median age: 97 days), transplanted valves showed true annular and leaflet growth — with low immunosuppression and no valve-related reinterventions. The

en

05:10

🧬🔬 From Barnyard to Human Chest: 216 Hours of Pig...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/28

🐖🫁 World First: Pig Lung Transplanted into Human 🧬🌍 In a groundbreaking step for xenotransplantation, a team in China successfully transplanted a genetically modified pig lung into a brain-dead human recipient. The lung functioned for 216 hours without hyperacute rejection, offering hope to thousands on organ waitlists. 🔬 Key breakthroughs: • 6-gene-edited donor pig • No Porcine Endogenous Retrovirus (PERV-C) detected 🦠 • Controlled immune response 🛡️ • PGD observed but stabilized 💉 📖

en

04:38

🧬 One Size Doesn’t Fit All: Tailoring NT-proBNP by Age

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/27

🧬 Pre-Heart Failure? Let Age Speak! 👵👴 New study in JACC compares fixed vs age-adjusted NT-proBNP cutoffs for defining pre–heart failure (Pre-HF) in over 22,000 adults across ARIC, MESA, and CHS cohorts. 📉 Key Insight: Age-adjusted cutoffs reduce overdiagnosis in older adults 🧓 and improve risk prediction for heart failure hospitalization 🏥. 📊 With better C-statistics, NRI, IDI, and a lower number needed to screen, the age-specific approach proves more precise—especially in those ≥75

en

05:26

🧬🛡️🔬 Nivolumab Before Surgery: A Lifesaving Combo in...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/27

🚨 Game-Changer in Lung Cancer! 🫁💉 The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯 ✅ 65.4% 5-year OS vs. 55.0% with chemo alone 🧬 pCR = 95.3% survival 📉 ctDNA clearance = better outcomes ⚖️ Time to rethink neoadjuvant strategies 📚 Read in NEJM: A landmark in thoracic oncology! #LungCancer #Immunotherapy #NSCLC #Nivolumab #Oncology #CancerResearch #PrecisionMedicine

en

774 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter